Revolutionizing Respiratory Care: How Type 2 Biologics Are Changing the Game for Severe Asthma and Beyond

In the rapidly evolving field of allergy and respiratory medicine, few advances have been as game-changing as the arrival of biologics that precisely target type 2 inflammation - the underlying driver in many cases of severe asthma, nasal polyps, and related conditions.

A new review in The Journal of Allergy and Clinical Immunology: In Practice offers a timely overview of the major players:

- omalizumab (anti-IgE)
- mepolizumab and reslizumab (anti-IL-5)
- benralizumab (anti-IL-5 receptor)
- dupilumab (anti-IL-4/IL-13)
- tezepelumab (anti-TSLP)

These monoclonal antibodies have dramatically reduced exacerbations, improved lung function, and cut reliance on oral corticosteroids for many patients.

The authors highlight how the introduction and broad use of these therapies mark an "unprecedented" shift in treatment paradigms, moving from broad immunosuppression to targeted pathway inhibition.

As real-world evidence grows, these biologics are increasingly considered earlier in the disease course for type 2–high patients - and their benefits may extend to other respiratory and allergic diseases sharing similar inflammatory pathways.

For allergists, pulmonologists, and patients struggling with uncontrolled symptoms, this class of drugs represents hope for better control and quality of life. The era of personalized, biology-driven respiratory care is here - and it's only expanding.

References:

https://www.jaci-inpractice.org/article/S2213-2198(25)01181-X/fulltext